BreezeBio

BreezeBio is a Brisbane, California-based biotechnology company that develops genetic medicines using its proprietary NanoGalaxy nanoparticle platform to deliver targeted gene therapies. The organization focuses on treatments for autoimmune conditions, such as Type 1 diabetes, and oncology, with its lead program BRZ-101 currently advancing through final preclinical studies before initiating human clinical trials. The enterprise has raised a total of $94.94 million in venture capital funding to date, which includes a recent $60 million Series B round and a prior $33.86 million financing tranche. Originally spun out of scientific research conducted at UC Berkeley, the firm has established strategic partnerships with global pharmaceutical entities, including a joint research and licensing agreement with Genentech. Formerly operating under the name GenEdit, the company was founded in 2016 by Kunwoo Lee, Hyo Min Park, and Niren Murthy.